IKNA Ikena Oncology, Inc. Stock Quote

IKNA [NASD]

Index	-	P/E	-	EPS (ttm)	-	Insider Own	0.10%	Shs Outstand	35.85M	Perf Week	-1.74%
Market Cap	456.54M	Forward P/E	-	EPS next Y	-1.56	Insider Trans	0.00%	Shs Float	35.83M	Perf Month	13.87%
Income	-	PEG	-	EPS next Q	-0.42	Inst Own	77.20%	Short Float	4.23%	Perf Quarter	-2.26%
Sales	9.44M	P/S	48.36	EPS this Y	-163.20%	Inst Trans	6.93%	Short Ratio	11.61	Perf Half Y	-
Book/sh	6.03	P/B	2.15	EPS next Y	46.90%	ROA	-	Target Price	-	Perf Year	-
Cash/sh	7.50	P/C	1.73	EPS next 5Y	-	ROE	-	52W Range	9.63 - 37.61	Perf YTD	-59.47%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	44.00%	52W High	-65.51%	Beta	-
Dividend %	-	Quick Ratio	8.80	Sales past 5Y	-	Gross Margin	-	52W Low	34.68%	ATR	1.03
Employees	33	Current Ratio	8.80	Sales Q/Q	25.00%	Oper. Margin	-	RSI (14)	54.13	Volatility	8.69% 8.98%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-139.50%	Profit Margin	-	Rel Volume	1.98	Prev Close	13.10
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	130.44K	Price	12.97
Recom	1.50	SMA20	3.03%	SMA50	9.36%	SMA200	-18.22%	Volume	258,372	Change	-0.99%

May-05-21

Resumed

Credit Suisse

Outperform

$30

Apr-26-21

Resumed

Credit Suisse

Outperform

$30

Apr-20-21

Initiated

William Blair

Outperform

Apr-20-21

Initiated

Jefferies

Buy

Apr-20-21

Initiated

Credit Suisse

Outperform

$30

Sep-02-21 07:00AM	Ikena Oncology to Participate in September 2021 Virtual Investor Conferences GlobeNewswire
Aug-12-21 07:00AM	Ikena Oncology Reports Second Quarter 2021 Financial Results and Provides Update on Key Programs GlobeNewswire +7.50%
Jul-08-21 07:00AM	Ikena Oncology to Participate in Targeted Oncology Panel at the William Blair Biotech Focus Conference 2021 GlobeNewswire
Jun-26-21 05:18AM	Companies Like Ikena Oncology (NASDAQ:IKNA) Are In A Position To Invest In Growth Simply Wall St.
May-26-21 07:00AM	Ikena Oncology to Participate in the 2021 Jefferies Virtual Healthcare Conference Business Wire
May-13-21 07:00AM	Ikena Oncology Reports First Quarter 2021 Financial Results and Outlines Key Corporate Objectives for 2021 Business Wire -13.61%
Apr-15-21 07:00AM	Ikena Oncology Appoints Dr. Maria Koehler to its Board of Directors Business Wire
Mar-30-21 04:05PM	Ikena Oncology Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters Option to Purchase Additional Shares Business Wire -9.54%
Mar-25-21 08:55PM	Ikena Oncology Announces Pricing of Initial Public Offering Business Wire

Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience